Dr. Axe Wire · Study decoded · health

Gut-Made Fat Linked to Calmer Pediatric MS in Two Cohorts

A gut bacteria byproduct found in blood and stool was tied to fewer MS flares and scan changes in children.

By Dr. Josh Axe · November 9, 2026 · 1 source · Understand

Photo: Pexels

At a glance

What they found: Children with more propionate, a gut bacteria byproduct, had calmer MS across three measures, and a second group of similar size showed the same pattern.
Who was studied: Children and teens recently diagnosed with pediatric-onset multiple sclerosis, studied in two separate large cohorts.

A study published November 6, 2026 in Cell Reports Medicine found that propionate, a short-chain fatty acid made by gut bacteria, was consistently linked to lower disease activity in children and teens recently diagnosed with multiple sclerosis.

Researchers measured short-chain fatty acids, compounds found in fermented foods and made when gut bacteria ferment dietary fiber, in paired blood and stool from a large group of children and teens shortly after their first MS symptoms appeared. Propionate consistently tracked with a protective pattern across three clinical and imaging activity measures, repeating in a second, similarly sized cohort for both blood and stool, according to the authors.

Plasma propionate correlated with gut bacteria known to produce short-chain fatty acids, but propionate levels did not correlate with how much dietary fiber the children consumed.

Short-chain fatty acids are a main way gut bacteria communicate with the immune and nervous systems, part of the gut-brain axis, and are generally thought to dampen inflammatory signaling, though this study didn't test that mechanism directly. Because propionate didn't line up with fiber intake, the authors note that eating more fiber may not reliably raise it. They write that direct propionate administration, rather than fiber supplementation, may be worth testing in proof-of-concept trials for MS activity.

Propionate is consistently associated with a protective effect on three clinical and imaging activity-related outcomes.

Study authorsCell Reports Medicine, 2026

This is an observational link, not proof propionate itself lowers disease activity. Sample size was not reported, and the fiber-propionate mismatch raises an open question about how propionate is made or absorbed. Trials testing propionate directly are the next step the authors point toward.

Dr. Axe’s Take

Propionate not tracking with fiber intake tells me this isn't a simple fix of eating more fiber and expecting protection. The gut bacteria doing the converting, and how well a child absorbs propionate, likely matter as much as the plate itself. For a family facing pediatric MS, I'd still build meals around fermented foods like yogurt, kefir and sauerkraut plus fiber-rich vegetables, since those feed the broader microbial community, even though this study can't promise that alone raises propionate. I'd pair that with working alongside the treating neurologist, never changing any prescribed MS therapy based on a dietary finding like this one.

— Dr. Axe

Take the Gut Health Quiz →

Study summary

Who: Children and teens recently diagnosed with pediatric-onset multiple sclerosis, studied in two separate large cohorts of similar size; exact sample size not reported.
Design: Observational cohort study measuring short-chain fatty acids in paired plasma and stool samples, reproduced in an independent external cohort.
Dose: Not applicable; observational measurement study, not an intervention or supplement trial.
Primary result: Propionate was consistently associated with lower disease activity across three clinical and imaging measures in both cohorts; exact absolute values not reported.
Secondary: Plasma propionate correlated with gut bacteria known to produce short-chain fatty acids. Propionate levels did not correlate with dietary fiber intake.
Funding / conflicts: Funders listed in the journal record: National Multiple Sclerosis Society; National Institute of Neurological Disorders and Stroke. Competing interests: Authors receive research grants from companies; one serves on advisory boards; authors consult for a company; one receives speaker fees.
Date: Nov 6, 2026